About ImPact Biotech

ImPact Biotech is focused on the development and launch of Padeliporfin VTP Therapy, a targeted treatment for selective tumor ablation. The company is headquartered in Israel, with divisions in USA and France as well as its own GMP-certified (Good Manufacturing Practice) facility and research center in Israel.

Leadership
Barak Palatchi Chief Executive Officer
Orit Schwartz Global Head of Technical Operations
Eyal Morag Chief Medical Officer
Guy Schmidt Global Head of Business Development
Louis-Christian Clauss Global Head of Regulatory Affairs and Pharmaco-Vigilance.
Roei Sella Chief Financial Officer
Barak Palatchi Chief Executive Officer
Orit Schwartz Global Head of Technical Operations
Eyal Morag Chief Medical Officer
Guy Schmidt Global Head of Business Development
Louis-Christian Clauss Global Head of Regulatory Affairs and Pharmaco-Vigilance.
Roei Sella Chief Financial Officer
Sharon Yarkoni Global Head of Quality Assurance
Shlomo Lempert Global Head of Human Resources
Inna Krasnopolskaya Global Head of Clinical Development
Sharon Yarkoni Global Head of Quality Assurance
Shlomo Lempert Global Head of Human Resources
Inna Krasnopolskaya Global Head of Clinical Development